Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for aggressive breast cancer: personalized therapy shows promise

NCT ID NCT02810743

Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this aggressive cancer type.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ddAC-CP-Olaparib and ddAC-mini CTC chemotherapy with stem cell rescue
What this could lead to
If successful, this could offer a more effective, personalized treatment for high-risk BRCA1-like breast cancer, potentially improving survival rates.
What could go wrong
This is a phase III trial but with only 174 participants, results may not apply to all patients. The intensified chemotherapy carries significant risks, including side effects from stem cell rescue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 174 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2017

Expected to finish

Dec 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women and men with stage III adenocarcinoma of the breast harboring signs of a breast cancer with features of homologous recombination deficiency (HRD) * Age of 18-65 years * The tumor must be HER2-negative * Treatment must start within 8 weeks after the last surgical resection * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Exclusion Criteria: * Previous radiation therapy * Previous chemotherapy * Any previous treatment with a PARP-inhibitor, including olaparib * Pre-existing neuropathy from any cause in excess of Grade 1 * Chronic concomitant use of known strong or moderate CYP3A inducers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • AZVU

    Amsterdam, 1081 HV, Netherlands

  • Antoni van Leeuwenhoek

    Amsterdam, 1066 CX, Netherlands

  • Erasmus Medical Center Cancer Institute

    Rotterdam, 3015CE, Netherlands

  • Hopital Tenon, University Marie-Curie

    Paris, France

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • LUMC

    Leiden, 2333 ZA, Netherlands

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • Medical spectrum Twente

    Enschede, Overijssel, 7500 KA, Netherlands

  • Radboud UMC

    Nijmegen, 6225GA, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

  • University Medical Center Utrecht

    Utrecht, 3584CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.